What Rakuten Medical’s deal with LOTTE Biologics signals for photoimmunotherapy scale-up
Rakuten Medical taps LOTTE Biologics for global supply of its Alluminox cancer platform. Find out what this deal means for photoimmunotherapy’s future.
Pharma & Biotech
Pharma & Biotech
With AlloJoin Phase 3 in motion, Fosun Kairos takes lead on stem cell therapy rollout in China
ElpasBio partners with Fosun Kairos to commercialize AlloJoin stem cell therapy for KOA in China. Find out what this deal means for the cell therapy market.
Pharma & Biotech
How Celltrion’s HER2–CD3 bispecific could compete in the T-cell engager arena
Celltrion is going all-in on oncology biologics with ADCs, msAbs, and U.S. biomanufacturing scale-up. Find out what this shift means for global competition.
Pharma & Biotech
Akeso’s cadonilimab outperforms PD-1 inhibitors in real-world gastric cancer study
Cadonilimab outperforms PD-1 inhibitors in PD-L1-low gastric cancer patients. Find out what this means for global immunotherapy standards.
Pharma & Biotech
GT Biopharma submits IND for GTB-5550 TriKE targeting B7-H3 expressing solid tumors with NK cell activation
Find out how GT Biopharma’s IND filing for its B7-H3-targeted TriKE GTB-5550 could advance NK cell immunotherapy for solid tumors.
Pharma & Biotech
Lilly and NVIDIA commit $1bn to AI co-innovation lab for next-gen drug discovery
Eli Lilly and Company and NVIDIA have announced the formation of a co-innovation lab aimed at accelerating drug discovery using AI, robotics, and advanced compute. With a planned $1 billion investment over five years, the lab will leverage NVIDIA’s BioNeMo platform and Vera Rubin architecture alongside Lilly’s drug development expertise. The initiative represents one of
Pharma & Biotech
HMNC Brain Health reports Phase 2b efficacy signals for BH-200 in genetically defined depression patients at ACNP
Find out how HMNC Brain Health’s Phase 2b BH-200 data at ACNP reveal genetic responder signals that could advance precision psychiatry in depression treatment.
Pharma & Biotech
Ocugen’s OCU410 shows early Phase 2 promise as a modifier gene therapy for geographic atrophy in dry AMD
Find out how Ocugen’s early Phase 2 results for OCU410 are shaping a new gene therapy approach for geographic atrophy in dry AMD.
Pharma & Biotech
Clinical data show Vaxart oral norovirus vaccine induces maternal and infant immunity
Find out how Vaxart’s oral bivalent norovirus vaccine induced immune responses in lactating women and enabled antibody transfer to breastfed infants.
Pharma & Biotech
LUCE-1 Phase 1/2 study fully enrolled as AAVantgarde evaluates AAVB-081 gene therapy in Usher syndrome type B retinitis pigmentosa
Find out how AAVantgarde Bio’s fully enrolled LUCE-1 Phase 1/2 trial advances AAVB-081 gene therapy development for Usher syndrome-related retinitis pigmentosa.